Celldex Therapeutics (CLDX) Accumulated Expenses (2010 - 2026)

Celldex Therapeutics' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $38.4 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 50.92% year-over-year to $38.4 million; the TTM figure through Mar 2026 stood at $38.4 million (up 50.92% YoY), while the FY2025 annual figure was $47.0 million, up 38.97% from the prior year.
• Accumulated Expenses was $38.4 million for Q1 2026 at Celldex Therapeutics, down from $47.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $47.0 million in Q4 2025 to a low of $9.2 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $22.6 million across 5 years, with a median of $18.6 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses rose 1.52% in 2023, then jumped 87.07% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $12.8 million in 2022, then surged by 71.63% to $22.0 million in 2023, then soared by 53.62% to $33.8 million in 2024, then surged by 38.97% to $47.0 million in 2025, then retreated by 18.31% to $38.4 million in 2026.
• The last three Accumulated Expenses figures came in at $38.4 million (Q1 2026), $47.0 million (Q4 2025), and $39.7 million (Q3 2025), per Business Quant data.